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A Prospective, Randomized, 6-Month Comparison
of the Coronary Vasomotor Response Associated
With a Zotarolimus- Versus a Sirolimus-Eluting Stent
Differential Recovery of Coronary Endothelial Dysfunction
Jin Won Kim, MD, PHD, Hong Seog Seo, MD, PHD, Jae Hyoung Park, MD, Jin Oh Na, MD,
Cheol Ung Choi, MD, Hong Euy Lim, MD, PHD, Eung Ju Kim, MD, PHD,
Seung-Woon Rha, MD, PHD, Chang Gyu Park, MD, PHD, Dong Joo Oh, MD, PHD
Seoul, Korea
Objectives We prospectively compared coronary endothelial dysfunction in patients with zotarolimus-eluting stent (ZES)
versus sirolimus-eluting stent (SES) implantation at 6-month follow-up.
Background A ZES has been associated with uniform and rapid healing of the endothelium.
Methods Fifty patients were randomly treated with intravascular ultrasound-guided stenting with a single stent to the mid-
segment of the left anterior descending artery (20 ZES, 20 SES, and 10 bare-metal stents), and endothelial func-
tion was estimated before and after intervention at 6-month follow-up by incremental acetylcholine (Ach) (10,
20, 50, and 100 g/min) and nitrate (200 g/min) infusions into the left coronary ostium. The vascular re-
sponse was quantitatively measured in the 5-mm segments proximal and distal to the stent.
Results In the drug-eluting stent groups, more intense vasoconstriction to incremental doses of Ach was observed at
6-month follow-up compared with the responses before stenting. Endothelial function associated with the ZES
was more preserved at 6-month follow-up compared with the SES. Vasoconstriction to Ach was more prominent
in the distal segments than the proximal segments in both the ZES and SES groups. Endothelium-independent
vasodilation to nitrate did not differ significantly among the study groups.
Conclusions Vasoconstriction in response to Ach in the peri-stent region was less pronounced in the ZES group than the
SES group at 6-month follow-up, which suggests that endothelial function associated with ZES can be more
preserved than the SES. (J Am Coll Cardiol 2009;53:1653–9) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.051f
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woronary stenting leads to disruption of the endothelial
ayer and leaves a thrombogenic metallic surface exposed to
he blood stream. Finn et al. (1) showed that sirolimus or
aclitaxel released from a drug-eluting stent (DES) im-
aired the normal healing processes of the injured arterial
all, even over a period of 40 months after implantation,
nd the heterogeneity of healing in the stents was associated
ith late stent thrombi. Our previous report (2) provided in
ivo evidence that both sirolimus-eluting stents (SES)
Cypher, Cordis Corporation, Hialeah, Florida) and
aclitaxel-eluting stents (Taxus, Boston Scientific Corpora-
ion, Natick, Massachusetts) can equally impair endothelial
rom the Cardiovascular Center, Korea University, Guro Hospital, Seoul, Korea.
his study was supported by the Seoul R & BD Program (10526) to Drs. Chang Gyu
ark and Seo.n
Manuscript received August 14, 2008; revised manuscript received January 12,
009, accepted January 12, 2009.unction and that their effects were demonstrable 6 months
fter implantation, especially in the arterial segments distal
o the DES 6 months after stenting.
A zotarolimus-eluting stent (ZES) (Endeavor, Medtronic
ascular, Inc., Santa Rosa, California) has been reported to
romote rapid and uniform healing of the endothelium (3), but
ittle is known about the functional impairment of the endo-
helium after ZES implantation. Therefore, this study was
rospectively designed to compare coronary endothelial dys-
unction in patients with a ZES versus a SES or a bare-metal
tent (BMS) (Driver, the ZES platform BMS, Medtronic
ascular) at pre- and post-intervention 6-month follow-up.
ethods
tudy patients. A total of 55 patients who were diagnosed
ith stable angina and treated with a single stent for a de
ovo single lesion of the left anterior descending artery were
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Endothelial Dysfunction of DES May 5, 2009:1653–9enrolled. The operators were not
blinded to group assignment, be-
cause preparation requirements
were needed for procedures. Af-
ter the patient took a consent
form, randomization was done
by the research nurse with a se-
quentially numbered, opaque,
sealed envelope in a 2:2:1 ratio.
All patients were prospectively
recruited from the Department
of Cardiology at Guro Hospital,
Korea University, Seoul, Korea.
ntravascular ultrasound (IVUS)-guided stenting was per-
ormed in all patients. Stenting was performed up to
inimum stent lumen cross sectional area 80% of the
verage of proximal and distal reference lumen area and full
tent-vessel wall apposition. Additional adjunctive balloon-
ng with noncompliant balloon was applied to a shorter area
han the stent length to avoid areas subject to balloon injury
ntil these criteria were reached. The exclusion criteria were
he presence of a 50% stenotic lesion except for a culprit
esion, 50% coronary vasoconstriction in response to
cetylcholine (Ach) infusion during the pre-intervention
est, a history of acute coronary syndrome or coronary
asospasm, ejection fraction 30%, in-stent or in-segment
estenosis (50%), reference diameters 2.5 mm, or other
erious medical conditions. This study was approved by the
nstitutional Review Board of Korea University. Written
nformed consent was obtained from all patients before
tudy entry.
rotocol for evaluation of endothelial function. All anti-
nginal agents that influence vasomotor tone, including
ong-acting nitrate, calcium-channel blockers, and beta-
lockers, were withheld for at least 72 h before coronary
ngiography except for sublingual nitroglycerin as needed.
ndothelial function was estimated by measuring the cor-
nary vasoreactivity in response to Ach infusion into the left
oronary ostium at the pre-intervention and 6-month
ollow-up. Before wiring to the target lesion, vasomotor
eactivity was estimated by infusing incremental doses of
ch into the left coronary ostium through a Judkins guiding
atheter (Ach1, 10 g; Ach2, 20 g; Ach3, 50 g; and
ch4, 100 g for 1 min, performed at an infusion rate of 5
l/min); a 5-min interval was allowed between doses.
hen the maximum dose was reached, an intracoronary
olus injection of nitroglycerin (200 g) was administered.
nd-diastolic images for each segment were chosen and
nalyzed with the automated edge detection program (FD-
0, Philips, Best, the Netherlands). Two orthogonal views
ith less foreshortening or without overlapping of side
ranches were selected and averaged for biplane assessment
y 2 experts blinded to stent type. Two segments in study
essel were chosen for analysis, specifically, 5-mm proximal
nd distal to the site of stenting. Changes in coronary diameter
Abbreviations
and Acronyms
Ach  acetylcholine
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
SES  sirolimus-eluting
stent(s)
ZES  zotarolimus-eluting
stent(s)n response to Ach and nitrate coronary infusion were ex- mressed as percent changes versus baseline angiograms. At the
-month follow-up, endothelial vasomotor reactivity was esti-
ated with the same method described in the preceding text.
nter- and intra-observer variability for repeated measurements
f quantitative coronary angiography in the same recordings of
0 randomly selected patients were 0.056  0.04 mm and
.018  0.04 mm, respectively.
tatistical analysis. Commercially available computer soft-
are (SPSS, version 16.0, SPSS, Inc., Chicago, Illinois) was
sed for all analyses. All continuous data are presented as mean
SD. Group demographic data were compared with a 1-way
nalysis of variance with a Scheffe test for multiple comparisons
or continuous variables, or analysis of variance on ranks for
ategorical variables. To minimize the potential influence of
ifferences in baseline characteristics, changes in coronary
iameters in response to drug infusions among groups were
ompared with a general linear model with the stent length and
ate loss as covariates. For within-group comparisons, such as
hanges in proximal versus distal sites, a paired Student t test
as used. Statistical significance was accepted at a p  0.05.
esults
t pre-intervention Ach test, 5 patients with more than
0% vasoconstriction in response to any dose of Ach were
xcluded, and thus the remaining 50 patients were randomly
ssigned to 3 groups (20 SES, 20 ZES, and 10 BMS).
ix-month follow-up angiography was done in all patients
xcept for 1 patient in the SES group who was lost to
ollow-up. One patient each in the ZES and BMS groups
ad in-stent restenosis (Fig. 1).
Table 1 summarized the baseline characteristics of the
atients. At 6-month follow-up, there were no significant
ifferences of medications among 3 groups except for clopi-
ogrel, which was discontinued in the BMS group after 1
onth. The IVUS demonstrated that the plaque burden at
ites 5-mm proximal and distal to stents were not different
mong the 3 groups (proximal sites: 24.9 11.6 vs. 25.7 13.0
s. 24.4 12.8, pNS; distal sites: 19.9 7.9 vs. 21.1 11.8
s. 22.4 9.9, pNS; SES vs. ZES vs. BMS, respectively) and
onfirmedno dissections at both proximal and distal to stents in all
atients. Six-month late loss associated with SESwas significantly
ower (0.13 mm) compared with those of ZES or BMS (0.61
m, p  0.002 and 0.74 mm, p  0.001, respectively).
ndothelial vasomotor reactivity among the ZES, SES,
nd BMS groups. Longer stents were used in the DES
roup compared with the BMS group (Table 2). No differ-
nces were observed among the SES, ZES, and BMS groups
n terms of reference segment diameter proximal and distal to
he stents (Table 2). The segments proximal to the stents were
ore strongly constricted to the Ach1 to Ach4 doses of the
ch infusion in the SES group compared with the BMS
roup. In contrast, between the ZES and BMS group, a
ignificant difference in vasomotor reactivity was observed after
nly the Ach4 dose of the Ach infusion (Table 2). The
agnitude of the estimated differences in vascular changes was
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May 5, 2009:1653–9 Endothelial Dysfunction of DESildly attenuated after adjustment for stent length and late loss
s potential confounding factors. However, the differences
mong SES, ZES, and BMS remained significant (Table 2,
ig. 2).
The segment distal to the stent was more strongly con-
tricted to the Ach1 to Ach4 doses of the Ach infusion in the
ES group and to the Ach2 to Ach4 doses of the Ach infusion
n the ZES group as compared with the BMS group (Table 2).
he diameter changes between the SES and the ZES had
ignificant differences of vasoreactivity in response to the Ach1
o Ach4 doses in sites distal to the stents but not the sites
roximal to the stents (Fig. 2). The diameter changes in
esponse to the Ach infusion were greater at the sites distal to
Figure 1 Study Profile
Ach  acetylcholine; BMS  bare-metal stent(s); ISR  in-stent restenosis; SES 
Baseline Characteristics
Table 1 Baseline Characteristics
SES (n  19)
Age, yrs 62.4 8.8
Male (%) 9 (47)
EF (%) 52.2 8.2
Underlying disease (%)
HTN 5 (26)
DM 4 (21)
Smoking 4 (21)
Obesity (BMI 25 kg/m2) 4 (21)
LDL-C (mg/dl) 114.2 23.9
Family history of CVD 5 (26)
Medications at 6 months
Statin 17 (89.4)
ARB/ACEI 6 (30)
ARB/ACEI  angiotensin-receptor blocker/angiotensin-converting enz
cardiovascular disease; DM  diabetes mellitus; EF  ejection fraction; HTN
sirolimus-eluting stent(s); ZES  zotarolimus-eluting stent(s).he stent than proximal to the stent in both the SES and ZES
Table 2).
ngiographic analysis: endothelial dysfunction between
re-intervention and 6-month post-intervention. When
omparing the diameter changes to the Ach infusion
etween the pre- and post-intervention, there was a more
ntense vasoconstriction in the SES group than the ZES
roup. The degree of vasoconstriction was greater at the
-month post-stenting in the proximal segments after the
ch2 to Ach4 doses of the Ach infusion and in the distal
egments after the Ach1 to Ach4 doses of the Ach
nfusion in the SES group as compared with pre-
ntervention. However, in the ZES group, the significant
imus-eluting stent(s); ZES  zotarolimus-eluting stent(s).
ZES (n  19) BMS (n  9) p Value
60.2 10.2 59.7 9.9 NS
10 (52) 5 (56) NS
51.2 8.1 53.3 8.1 NS
6 (31) 3 (30) NS
4 (21) 2 (20) NS
5 (26) 2 (20) NS
6 (31) 3 (30) NS
108.5 28.2 115 25.1 NS
4 (21) 3 (30) NS
17 (89.4) 100 (9) NS
6 (30) 3 (30) NS
hibitor; BMI  body mass index; BMS  bare-metal stent(s); CVD sirolyme in
 hypertension; LDL-C  low-density lipoprotein cholesterol; SES 
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Endothelial Dysfunction of DES May 5, 2009:1653–9hanges between the pre-stenting and 6-month post-
tenting were observed only in the distal segments after
he Ach3 to Ach4 doses of the Ach infusion (Fig. 3).
asoreactivity in response to nitrate infusion. The ZES,
ES, and BMS groups showed no differences of vasodila-
ion in response to nitrate infusion between the pre- and
ost-intervention or between the sites proximal and distal to
tents (Table 2).
iscussion
n the present study, endothelial vasomotor reactivity at
he 6-month post-intervention was significantly impaired
Comparison of Vasoreactivity in Proximaland Distal Segments Among SES, ZES, and BM
Table 2 Comparison of Vasoreactivity in Proand Distal Segments Among SES, Z
SES
Mean stent length, mm 27.0 6
Stent deployment pressure, mm Hg 14.6 1
Mean stent diameter 3.06 0
Pre-intervention diameter stenosis 74.4 3
Proximal to stent
Reference diameter, mm 3.17 0
Diameter change to Ach1, %
Crude 9.46 5
Adjusted‡ 8.52 3
Diameter change to Ach2, %
Crude 18.8 8
Adjusted‡ 17.3 3
Diameter change to Ach3, %
Crude 21.2 1
Adjusted‡ 18.8 5
Diameter change to Ach4, %
Crude 24.3 1
Adjusted‡ 22.8 5
Diameter change to NTG, %
Crude 8.09 5
Adjusted‡ 8.21 3
Distal to stent
Reference diameter, mm 2.78 0
Diameter change to Ach1, %
Crude 44.5 1
Adjusted‡ 39.0 4
Diameter change to Ach2, %
Crude 52.2 2
Adjusted‡ 50.0 8
Diameter change to Ach3, %
Crude 63.1 1
Adjusted‡ 60.9 7
Diameter change to Ach4, %
Crude 71.1 1
Adjusted‡ 69.9 9
Diameter change to NTG, %
Crude 7.76 5
Adjusted‡ 8.15 4
Acetylcholine (Ach)1, 10 g; Ach2, 20 g; Ach3, 50 g; and Ach4, 10
SEM, adjusted means for differences among SES, ZES, and BMS group
distal versus proximal, p  0.05.
NTG  nitroglycerin; other abbreviations as in Table 1.n both the ZES and SES groups compared with the aMS group. However, the endothelial function associ-
ted with the ZES was more preserved at the 6-month
ollow-up compared with the SES. This is the first
ublished comparison to provide in vivo evidence that
ndothelial-dependent vasomotor reactivity associated
ith the ZES could be more preserved compared with
he SES.
There is compelling clinical evidence that ZES carries an
xtremely low risk of late stent thrombosis (4). In humans,
he ZES is associated with a greater amount of neointimal
yperplasia by IVUS at 8 months (5) and a homogeneous
omplete healing by optical coherence tomography (OCT)
l
nd BMS
ZES BMS
24.7 6.88† 21.4 2.85
13.6 2.31 13.8 1.55
3.00 0.33 3.12 0.37
73.9 2.82 72.3 1.93
3.19 0.38 3.13 0.38
4.32 3.87 4.47 8.12
3.95 2.77 5.43 4.27
9.31 13.1 3.89 6.63
8.76 2.91 5.89 4.37
9.11 11.8 5.88 9.80
8.17 5.15 7.67 6.39
13.8 8.21 6.31 8.95
12.7 4.44† 8.99 6.41
7.62 10.1 5.06 4.37
7.66 2.67 4.88 3.55
2.81 0.54 2.91 0.43
8.91 7.21 6.49 7.01
7.42 3.11 8.59 5.87
15.2 13.3 6.71 5.15
14.9 5.22† 6.91 6.10
24.4 20.3 8.11 7.21
22.3 5.33† 10.6 6.99
38.5 24.4 7.99 6.42
37.7 6.77†§ 13.2 9.32
6.47 5.74 4.66 6.54
7.41 3.44 4.49 4.77
SES versus BMS, p  0.001; †ZES versus BMS, p  0.05; ‡mean 
ding to stent length and late loss; §distal versus proximal, p 0.001;S
xima
ES, a
.16*
.99
.28
.61
.54
.21
.72*
.41
.81*
0.9
.57*
4.6
.96*
.81
.85
.47
7.1
.25*§
4.1
.81*§
6.8
.15*§
5.6
.17*§
.53
.13
0 g. *
s accort 6 months compared with the SES (6). In the current
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May 5, 2009:1653–9 Endothelial Dysfunction of DEStudy, despite a greater degree of endothelial dysfunction
ompared with the BMS, the ZES was associated with
esser vasoconstriction to Ach compared with the SES. The
resent study was prospectively designed to compare the
hanges in endothelial dysfunction in response to Ach
nfusion between pre-stenting and 6-month post-stenting,
nd hence the influence of existing endothelial dysfunction
er se without relation to the stent could be minimized. We
peculated that, on the basis of optical conference tomog-
aphy data (6) and current results, the more preserved
ndothelial function at 6 months in the ZES could be
ssociated with more complete endothelial coverage com-
ared with the SES and contribute to the safety profiles in
erms of late thrombosis, although actual data regarding the
irect relationship between endothelial function and healing
ver struts or clinical outcomes are lacking.
The differential effects of DES on endothelial function could
e explained by the characteristics of the loaded drug. Obata
t al. (7) showed that sirolimus released from the SES reduced
he level of vascular endothelial growth factor in the coronary
irculation 2 weeks after SES implantation. An in vitro study
y Jabs et al. (8) reported continuous sirolimus exposure causes
mpaired endothelium-dependent vascular relaxation by stim-
lation of mitochondrial reactive oxygen species release. How-
ver, until now, there has been no comparable evidence
Figure 2 Comparing Vasoreactivity Between SES and ZES
The diameter changes between the SES and the ZES had significant differences o
but not the sites proximal to the stents. *p value, SES versus ZES. LAD  left anteegarding the potency of sirolimus and zotarolimus. Another totential explanation for the early restoration of endothelial
unction after ZES implantation might relate to the rapid
lution of the coating drug. Whereas, in the SES, the loaded
rug is released from the stent up to 60 days after stent
mplantation, the ZES maintains effective drug levels through
nitial loading of arterial tissue with the drug only during the
rst 2 weeks of elution from the stent (9), and thus local
oxicity is minimized. In addition, the unique characteristics of
he phosphorylcholine polymer could contribute to the differ-
ntial effects of DES (3). A recent study by Hamilos et al. (10)
howed that the biolimus A9-eluting stent, on the basis of a bio-
bsorbable polymer, showed a better-preserved endothelium-
ependent vasomotion response at adjacent stent segments
ompared with the SES. The phosphorylcholine-based
olymer of ZES has, despite the permanent polymer,
ydrophilic properties that are expected to generate less
nterfacial tension in the aqueous body environment and is
hus more highly biocompatible compared with the hydro-
hobic polymer of the SES, which has been shown to resist
brinogen adsorption and cause less platelet and monocyte
ctivation (3). Finally, the struts of the ZES were thinner
han those of the SES platform. A previous study reported
hat reduced arterial injury and restenosis are associated
ith thinner struts (11).
Despite strong evidence of more rapid restoration of endo-
reactivity in response to the Ach1 to Ach4 doses in sites distal to the stents
scending coronary artery; NTG  nitroglycerin; other abbreviations as in Figure 1.f vaso
rior dehelial dysfunction associated with ZES compared with SES, it
i
b
b
c
m
m
g
c
m
n
t
r
q
s
Z
d
a
S
r
p
v
a
f
a
e
e
a
d
t
d
C
T
f
t
A
T
H
R
H
G
k
R
1658 Kim et al. JACC Vol. 53, No. 18, 2009
Endothelial Dysfunction of DES May 5, 2009:1653–9s unknown whether the ZES is associated with any clinical
enefits. The late loss associated with ZES has been known to
e higher compared with those of SES and could influence the
linical outcomes. Nonetheless, in-stent late loss up to 0.75
m in low-risk populations is clinically acceptable in terms of
ajor adverse cardiac events (12). Therefore, despite the
reater in-stent late loss, taken together with our data, it is
onceivable that a second-generation DES, the ZES, could be
ore beneficial in specific clinical situations in which they are
eeded—for example, in the patients who inevitably discon-
inue dual antiplatelet agents within 12 months as guideline-
ecommended due to scheduled surgery or patients with
uestionable compliance for dual antiplatelet agents. To an-
wer these questions and clarify the clinical relevance of the
ES as related to preserved endothelial function, well-
esigned randomized clinical trials on special subpopulations
re warranted.
tudy limitations. The number of enrolled patients was
elatively small. Although angiographic images of both pre-
rocedure and follow-up studies were analyzed by side to side
iewing to compare the matched sites, it was hard to identify
nd estimate the exact same sites. The IVUS was not per-
ormed at 6-month follow-up, and thus the influence of plaque
t proximal and distal edges to stent could not be completely
xcluded. Another limitation was the possibility that tethering
Proximal Distal 
SES
 
0.173
0.080
0.023*
0.031*
0.025*
0.440
<0.001
<0.001
<0.001
<0.001
Ach1 Ach2
Figure 3 Comparing Vasoreactivity Between Pre- and Post-Inte
The diameter changes were greater in proximal segments after acetylcholine (Ach)
in the SES group. In the ZES group, the significant changes were observed only inffect by the stent itself could influence the results. Addition-lly, ethnicity might influence our results. Asians show a higher
egree of coronary vasoconstriction in response to Ach infusion
han Caucasians (13). To solve this issue, further studies on
iverse races will be required.
onclusion
his study provided in vivo evidence that endothelial
unction associated with the ZES could be more preserved
han after SES, despite a greater late loss of the ZES.
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